Display Settings:

Format

Send to:

Choose Destination

    Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10705-9.

    Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

    Kendall RL, Thomas KA.

    Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065.

    Vascular endothelial cell growth factor, a mitogen selective for vascular endothelial cells in vitro that promotes angiogenesis in vivo, functions through distinct membrane-spanning tyrosine kinase receptors. The cDNA encoding a soluble truncated form of one such receptor, fms-like tyrosine kinase receptor, has been cloned from a human vascular endothelial cell library. The mRNA coding region distinctive to this cDNA has been confirmed to be present in vascular endothelial cells. Soluble fms-like tyrosine kinase receptor mRNA, generated by alternative splicing of the same pre-mRNA used to produce the full-length membrane-spanning receptor, encodes the six N-terminal immunoglobulin-like extracellular ligand-binding domains but does not encode the last such domain, transmembrane-spanning region, and intracellular tyrosine kinase domains. The recombinant soluble human receptor binds vascular endothelial cell growth factor with high affinity and inhibits its mitogenic activity for vascular endothelial cells; thus this soluble receptor could act as an efficient specific antagonist of vascular endothelial cell growth factor in vivo.

    PMID: 8248162 [PubMed - indexed for MEDLINE]

    PMCID: 47846

    Supplemental Content

    Click here to read